Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery

Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer
Discovery

Results Outline Most Comprehensive Human Experience to Date for RNAi
Therapeutics Delivered With Lipid Nanoparticles (LNPs)

VANCOUVER, British Columbia, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Tekmira
Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of
RNA interference (RNAi) therapeutics, announced today that complete study
results have been published from a Phase I trial with ALN-VSP, a systemically
delivered RNAi therapeutic for the treatment of advanced solid tumors with
liver involvement, which utilizes Tekmira's lipid nanoparticle (LNP)
technology. ALN-VSP is being developed by Alnylam Pharmaceuticals, Inc.
(Nasdaq:ALNY).

"This published work further validates the longer-term safety and tolerability
of Tekmira's industry-leading LNP delivery platform, which is enabling the
anti-tumor activity reported in this paper. Our LNP technology, which
represents the most widely-used delivery technology in the RNAi field, is
driving the advancement of our own product pipeline, including our lead cancer
therapeutic TKM-PLK1, as well as the clinical-stage therapeutics of our
partners," said Dr. Mark J. Murray, Tekmira's President and CEO.

Tekmira has granted Alnylam a license to use Tekmira's LNP technology to
advance RNAi therapeutic products, including the products ALN-VSP, ALN-TTR and
ALN-PCS, and Tekmira remains eligible to receive milestones and royalties as
Alnylam's LNP enabled products are developed and commercialized. Tekmira will
receive a $5 million payment related to initiation of clinical trials for
ALN-VSP in China. Alnylam has guided that it expects to report results in
mid-2013 from its Phase II study with ALN-TTR02 in patients with ATTR, and
anticipates initiating a Phase III pivotal trial of ALN-TTR02 in late 2013.
Tekmira will receive a $5 million milestone payment upon ALN-TTR02 entering a
pivotal trial and royalties on commercial sales of ALN-TTR.

The most recently published paper is entitled "First-in-Man Trial of an RNA
Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver
Involvement" and appears as an OnlineFirst publication in the journal Cancer
Discovery (Tabernero et al., Cancer Discovery CD-12-0429; Published
OnlineFirst January 2013). More detailed information about the Phase I
Clinical Trial and Extension Study with ALN-VSP can be found in Alnylam's news
release dated January 30, 2013, which has been posted at www.alnylam.com.

About RNAi and Tekmira's LNP

RNAi therapeutics have the potential to treat a broad number of human diseases
by "silencing" disease causing genes. The discoverers of RNAi, a gene
silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for
Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery
technology to be effective systemically. Tekmira believes its LNP technology
represents the most widely adopted delivery technology for the systemic
delivery of RNAi therapeutics. Tekmira's LNP platform is being utilized in
multiple clinical trials by both Tekmira and its partners. Tekmira's LNP
technology (formerly referred to as stable nucleic acid-lipid particles or
SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles
that are effective in delivering RNAi therapeutics to disease sites in
numerous preclinical models. Tekmira's LNP formulations are manufactured by a
proprietary method which is robust, scalable and highly reproducible, and
LNP-based products have been reviewed by multiple FDA divisions for use in
clinical trials. LNP formulations comprise several lipid components that can
be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on
advancing novel RNAi therapeutics and providing its leading lipid nanoparticle
delivery technology to pharmaceutical partners. Tekmira has been working in
the field of nucleic acid delivery for over a decade and has broad
intellectual property covering LNPs. Further information about Tekmira can be
found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8319

Forward-Looking Statements and Information

This news release contains "forward-looking statements" or "forward-looking
information" within the meaning of applicable securities laws (collectively,
"forward-looking statements"). Forward-looking statements are generally
identifiable by use of the words "believes," "may," "plans," "will,"
"anticipates," "intends," "budgets," "could," "estimates," "expects,"
"forecasts," "projects" and similar expressions, and the negative of such
expressions. Forward-looking statements in this news release include Tekmira's
strategy, future operations, clinical trials, prospects and the plans of
management; RNAi (ribonucleic acid interference) product development programs;
Alnylam's ALN-VSP product development program as a treatment for cancer; the
development timeline and expected milestone payments associated with Alnylam's
ALN-TTR program; the advancement of products that utilize Tekmira's lipid
nanoparticle technology; expectations regarding the advancement of multiple
product candidates; the quantum and timing of further clinical data being
presented for LNP-enabled products; continued innovation and protection of LNP
technology; timing of the initiation of clinical trials and release of
clinical data from Tekmira's product candidates; the quantum and timing of
potential milestone and royalty payments; and the use of lipid nanoparticle
technology by Tekmira's licensees.

With respect to the forward-looking statements contained in this news release,
Tekmira has made numerous assumptions regarding, among other things: LNP's
status as a leading RNAi delivery technology; early results in human clinical
trials are indicative of the potential opportunity to treat a variety of
disease indications, including cancer; Tekmira's research and development
capabilities and resources; the timing and results of clinical data releases
and use of LNP technology by Tekmira's development partners and licensees; the
time required to complete research and product development activities; the
timing and quantum of payments to be received under licenses with Tekmira's
collaborative partners including Alnylam; and the sufficiency of budgeted
capital expenditures in carrying out planned activities. While Tekmira
considers these assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and social
uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause
Tekmira's actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking statements contained herein. Known risk factors
include, among others: the possibility that current and future data from the
human clinical trials with ALN-VSP and ALN-TTR02 conducted by Alnylam does not
and will not lead to favourable results for Tekmira's products or prospects;
the possibility that there will not be further clinical data on LNP-enabled
products in the quantum nor timing anticipated by Tekmira, or at all; the
possibility that Tekmira may not be able to innovate nor protect its LNP
technology; the possibility that other organizations have made advancements in
RNAi delivery technology that Tekmira is not aware of; the FDA will not
approve the commencement of Tekmira's planned clinical trials or approve the
use of Tekmira's products; difficulties, delays or inaccuracies in the
progress, timing, results and data from clinical trials and studies; the
possibility that Tekmira may not advance any further product candidates;
competition from other pharmaceutical or biotechnology companies; Tekmira's
development partners and licensees conducting clinical trials and development
programs will not result in expected results on a timely basis, or at all;
anticipated payments under licenses with Tekmira's collaborative partners,
including Alnylam, will not be received by Tekmira on a timely basis, or at
all, or in the quantum expected by Tekmira; IND applications may not be filed
on a timely basis, pre-clinical trials may not be completed, or clinical
trials started, when anticipated or at all; pre-clinical or clinical trials
may not generate results that warrant future development of the tested drug
candidate; funding from research and product development partners may not be
provided when required under agreements with those partners; and Tekmira has
not sufficiently budgeted for capital expenditures necessary to carry out
planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira
appears in Tekmira's annual report on Form 20-F for the year ended December
31, 2011 (Annual Report), which is available at www.sedar.com or at
www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified
in their entirety by this cautionary statement, and Tekmira disclaims any
obligation to revise or update any such forward-looking statements or to
publicly announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or developments,
except as required by law.

CONTACT: Investors
         Jodi Regts
         Director, Investor Relations
         Phone: 604-419-3234
         Email: jregts@tekmirapharm.com
        
         Media
         David Ryan
         Longview Communications Inc.
         Phone: 416-669-7906
         Email: dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo